Skip to main content
Top

2013 | OriginalPaper | Hoofdstuk

31. Hypertension: Mechanisms and Diagnosis

Auteur : Clive Rosendorff, MD, PhD, DScMed, FRCP, FACC, FAHA

Gepubliceerd in: Essential Cardiology

Uitgeverij: Springer New York

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Hypertension, defined as an arterial blood pressure (BP) of ≥140/90 mmHg, affects one in three US adults and is a major independent risk factor for myocardial infarction, stroke, and renal failure. Only 43 % of the total hypertensive population has their BP controlled to goal (<140/90 mmHg). Pre-hypertension refers to a BP of 120–139/80–89 mmHg and also increases cardiovascular risk, compared with normal BP (<120/80 mmHg). Definitions are provided for the terms essential hypertension, secondary hypertension, refractory (resistant) hypertension, pseudohypertension, white coat hypertension, masked hypertension, and hypertensive crisis. This chapter deals with definitions, measurement of BP, the initial workup of the hypertensive patient, target-organ damage (vascular hypertrophy, left ventricular hypertrophy, myocardial infarction, stroke, encephalopathy, chronic kidney disease, and retinopathy), hypertensive emergency and urgency, and risk factor profiling. The section on the pathogenesis of primary hypertension deals with genetic factors, increased cardiac output, excessive dietary sodium, renal sodium retention, increased activity of the renin–angiotensin system, increased sympathetic activity, increased peripheral resistance, abnormal cell membrane ion transport, endothelial function, and insulin resistance and hyperinsulinemia. Causes of secondary hypertension include renal artery stenosis, renal parenchymal disease, pheochromocytoma, and abnormalities of adrenocortical function.
Literatuur
1.
go back to reference MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–73.PubMedCrossRef MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–73.PubMedCrossRef
3.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, et al., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e12–e230. Roger VL, Go AS, Lloyd-Jones DM, et al., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e12–e230.
4.
go back to reference Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.PubMedCrossRef Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.PubMedCrossRef
5.
go back to reference Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef
6.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRef
7.
go back to reference Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals, Part 1: blood pressure measurement in humans. Hypertension. 2005;45:142–61.PubMed Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals, Part 1: blood pressure measurement in humans. Hypertension. 2005;45:142–61.PubMed
8.
go back to reference Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol. 1996;28:803–12. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol. 1996;28:803–12.
9.
go back to reference Rosendorff C. Ischemic heart disease in hypertension. In: Black HR, Elliott WJ, editors. Hypertension: A companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier; 2007. p. 327–39. Rosendorff C. Ischemic heart disease in hypertension. In: Black HR, Elliott WJ, editors. Hypertension: A companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier; 2007. p. 327–39.
11.
go back to reference Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761–88.PubMedCrossRef Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761–88.PubMedCrossRef
12.
go back to reference Rosendorff C. Stroke in the elderly—risk factors and some projections. Cardiovasc Rev Rep. 1999;20:244–8. Rosendorff C. Stroke in the elderly—risk factors and some projections. Cardiovasc Rev Rep. 1999;20:244–8.
13.
go back to reference Healton EB, Brust JC, Feinfeld DA, Thomson GE. Hypertensive encephalopathy and the neurological manifestations of malignant hypertension. Neurology. 1982;32:127–32.PubMedCrossRef Healton EB, Brust JC, Feinfeld DA, Thomson GE. Hypertensive encephalopathy and the neurological manifestations of malignant hypertension. Neurology. 1982;32:127–32.PubMedCrossRef
14.
15.
go back to reference Smith MC, Lazar A, Rahman M. Hypertension associated with renal parenchymal disease. In: Shrier RW, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Wouters Kluwer/Lippincott Williams and Wilkins; 2007. p. 1238–71. Smith MC, Lazar A, Rahman M. Hypertension associated with renal parenchymal disease. In: Shrier RW, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Wouters Kluwer/Lippincott Williams and Wilkins; 2007. p. 1238–71.
16.
go back to reference Ruilope L, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk–implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16(2):72–9.PubMedCrossRef Ruilope L, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk–implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16(2):72–9.PubMedCrossRef
17.
go back to reference Frank RN. The eye in hypertension. In: Izzo JL Jr, Sica DA, Black HR, editors. Hypertension Primer: the essentials of high blood pressure. 4th ed. Dallas/Philadelphia: Council for High Blood Pressure Research, American Heart Association and Lippincott Williams & Wilkins; 2008. p. 226–8. Frank RN. The eye in hypertension. In: Izzo JL Jr, Sica DA, Black HR, editors. Hypertension Primer: the essentials of high blood pressure. 4th ed. Dallas/Philadelphia: Council for High Blood Pressure Research, American Heart Association and Lippincott Williams & Wilkins; 2008. p. 226–8.
18.
go back to reference Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143–421. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143–421.
19.
go back to reference Hall JE, Mizelle HL, Hildebrandt DA, Brands MW. Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension. 1990;15(6):547–59.PubMedCrossRef Hall JE, Mizelle HL, Hildebrandt DA, Brands MW. Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension. 1990;15(6):547–59.PubMedCrossRef
20.
go back to reference Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens. 1996;10:633–9.PubMed Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens. 1996;10:633–9.PubMed
21.
go back to reference Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens. 2009;27:9–18.PubMedCrossRef Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens. 2009;27:9–18.PubMedCrossRef
22.
go back to reference Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis. 1994;23(2):171–5.PubMed Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis. 1994;23(2):171–5.PubMed
23.
go back to reference Laragh JH. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens. 1995;9:385–90.PubMed Laragh JH. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens. 1995;9:385–90.PubMed
24.
go back to reference Williams GH, Hollenberg NK. Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension. 1991;17 Suppl 1:181–5. Williams GH, Hollenberg NK. Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension. 1991;17 Suppl 1:181–5.
25.
26.
go back to reference Rosendorff C. Endothelin, vascular hypertrophy and hypertension. Cardiovasc Drugs Ther. 1996;10:795–802.CrossRef Rosendorff C. Endothelin, vascular hypertrophy and hypertension. Cardiovasc Drugs Ther. 1996;10:795–802.CrossRef
27.
go back to reference Reaven GM, Lithell H, Landsberg L. Hypertension and associated abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–81.PubMedCrossRef Reaven GM, Lithell H, Landsberg L. Hypertension and associated abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–81.PubMedCrossRef
29.
go back to reference Pohi MA, Wilcox CS. Renal vascular hypertension and ischemic nephropathy. In: Shrier RW, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Wouters Kluwer/Lippincott Williams & Wilkins; 2007. p. 1272–316. Pohi MA, Wilcox CS. Renal vascular hypertension and ischemic nephropathy. In: Shrier RW, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Wouters Kluwer/Lippincott Williams & Wilkins; 2007. p. 1272–316.
30.
go back to reference Elliott WJ. Renovascular hypertension: an update. J Clin Hypertens. 2008;10(7):522–33.CrossRef Elliott WJ. Renovascular hypertension: an update. J Clin Hypertens. 2008;10(7):522–33.CrossRef
31.
go back to reference Working Group. Update of the working group reports on chronic renal failure and renovascular hypertension. NIH Publication No. 95–3791. National Heart, Lung and Blood Institute, Washington, D.C.; 1995. Working Group. Update of the working group reports on chronic renal failure and renovascular hypertension. NIH Publication No. 95–3791. National Heart, Lung and Blood Institute, Washington, D.C.; 1995.
32.
go back to reference Kidney Diseases Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1–290. Kidney Diseases Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1–290.
33.
go back to reference Manger WM, Gifford Jr RW. Pheochromocytoma: diagnosis and treatment. J Clin Hypertens. 2002;4:62–72.CrossRef Manger WM, Gifford Jr RW. Pheochromocytoma: diagnosis and treatment. J Clin Hypertens. 2002;4:62–72.CrossRef
34.
go back to reference Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007;21(3):509–25.PubMedCrossRef Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007;21(3):509–25.PubMedCrossRef
35.
go back to reference Nadar S, Lip GY, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem. 2003;40(5):43452.CrossRef Nadar S, Lip GY, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem. 2003;40(5):43452.CrossRef
36.
go back to reference Calhoun DA. Management of hyperaldosteronism and hypercortisolism. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension Primer; the essentials of high blood pressure. 4th ed. Dallas: American Heart Association Council for High Blood Pressure Research; 2008. p. 564–7. Calhoun DA. Management of hyperaldosteronism and hypercortisolism. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension Primer; the essentials of high blood pressure. 4th ed. Dallas: American Heart Association Council for High Blood Pressure Research; 2008. p. 564–7.
37.
go back to reference Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92 Suppl 1:44–9.PubMedCrossRef Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92 Suppl 1:44–9.PubMedCrossRef
38.
go back to reference Bravo EL. Secondary hypertension: mineralocorticoid excess states. In: Black HR, Elliott WJ, editors. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: Saunders/Elsevier; 2007. p. 106–18. Bravo EL. Secondary hypertension: mineralocorticoid excess states. In: Black HR, Elliott WJ, editors. Hypertension: a ­companion to Braunwald’s heart disease. Philadelphia: Saunders/Elsevier; 2007. p. 106–18.
39.
go back to reference Gomez-Sanchez CE. Adrenal steroid synthesis and regulation. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension Primer: the essentials of high blood pressure. 4th ed. Dallas: Lippincott Williams & Wilkins; 2008. p. 61–4. Gomez-Sanchez CE. Adrenal steroid synthesis and regulation. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension Primer: the essentials of high blood pressure. 4th ed. Dallas: Lippincott Williams & Wilkins; 2008. p. 61–4.
go back to reference Izzo JL Jr, Sica DA, Black HR, editors. Hypertension Primer. The essentials of high blood pressure, 4th ed. Dallas: Council on High Blood Pressure Research, American Heart Association; 2008. Izzo JL Jr, Sica DA, Black HR, editors. Hypertension Primer. The essentials of high blood pressure, 4th ed. Dallas: Council on High Blood Pressure Research, American Heart Association; 2008.
go back to reference Kaplan NM, Victor RG. Kaplan’s clinical hypertension. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. Kaplan NM, Victor RG. Kaplan’s clinical hypertension. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
go back to reference The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. No. 98–4080. Bethesda: National Institutes of Health; 1997. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. No. 98–4080. Bethesda: National Institutes of Health; 1997.
Metagegevens
Titel
Hypertension: Mechanisms and Diagnosis
Auteur
Clive Rosendorff, MD, PhD, DScMed, FRCP, FACC, FAHA
Copyright
2013
Uitgeverij
Springer New York
DOI
https://doi.org/10.1007/978-1-4614-6705-2_31